Anuh Pharma Ltd
Thu 13/03/2025,15:59:19 | NSE : ANUHPHR
Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
Open
₹ 154.18
Previous Close
₹ 154.18
Volume
11076
Mkt Cap ( Rs. Cr)
₹769.32
High
₹ 156.95
Low
₹ 153.00
52 Week High
₹ 245.70
52 Week Low
₹ 149.98
Book Value Per Share
₹ 60.49
Dividend Yield
1.62
Face Value
₹ 5.00
What’s Your Call?
Collective community sentiment on Anuh Pharma Ltd
Your Vote -
Buy
85.00%
Hold
10.00%
Sell
5.00%
85.00%
20 users have voted
Market Depth
How many stocks are available to buy or sell and at what prices.
Buy Order Quantity
0%
Sell Order Quantity
100%
Bid Price
Qty
0.00
0
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
0
Bid Price
Qty
153.52
1
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
1
Option Chain
Analyzes market sentiment, predicts Anuh Pharma Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Anuh Pharma Ltd - Statement of deviation(s) or variation(s) under Reg. 32
-
Anuh Pharma Ltd - Non-Applicability Of Statement Of Deviation(S) And Variation(S) Under Regulation 32(1), Of The SEBI (Listin
-
Anuh Pharma Ltd - Corrigendum
-
Anuh Pharma Ltd - Copy of Newspaper Publication
-
Anuh Pharma Ltd - Integrated Filing- Financial
-
Anuh Pharma Ltd - Integrated Filing (Financial)
-
Anuh Pharma Ltd Q3 net profit down 45.89% at Rs 10.34 cr
-
Anuh Pharma Ltd - Financial Result Updates
-
Anuh Pharma Ltd - Results - Financial Results For December 31, 2024 (Quarter Ended 31St December, 2024)
-
Anuh Pharma Ltd - Outcome of Board Meeting
-
Anuh Pharma Ltd - Board Meeting Outcome for Board Meeting Outcome For Meeting Held On 07Th February, 2025
-
Anuh Pharma Ltd - Board Meeting Intimation
-
Anuh Pharma Ltd - Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results For The Quarter Ende
-
Anuh Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2024
-
Anuh Pharma Ltd - Certificate under SEBI (Depositories and Participants) Regulations, 2018
-
Anuh Pharma Ltd - Credit Rating
-
Anuh Pharma Ltd - Announcement under Regulation 30 (LODR)-Credit Rating
-
Anuh Pharma Ltd - Copy of Newspaper Publication
-
Anuh Pharma Ltd - Trading Window-XBRL
-
Anuh Pharma Ltd - Trading Window-XBRL
-
Anuh Pharma Ltd - Trading Window
-
Anuh Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 17, 2024
-
Anuh Pharma gets nod from WHO
Key fundamentals
Evaluate the intrinsic value of Anuh Pharma Ltd stock
| Name | March-24 | March-23 | March-22 | March-21 | March-20 |
|---|---|---|---|---|---|
| Assets | 293.2313 | 241.2214 | 216.8838 | 204.2412 | 206.7674 |
| Liabilities | 293.2313 | 241.2214 | 216.8838 | 204.2412 | 206.7674 |
| Equity | 25.056 | 25.056 | 25.056 | 25.056 | 12.528 |
| Gross Profit | 75.1491 | 51.2745 | 46.8455 | 44.5835 | 22.7681 |
| Net Profit | 60.0575 | 36.1796 | 30.5613 | 28.4363 | 14.3053 |
| Cash From Operating Activities | 12.9251 | 53.9016 | 28.8637 | -18.7347 | 48.9307 |
| NPM(%) | 9.28 | 6.85 | 6.27 | 6.58 | 4.66 |
| Revenue | 647.0043 | 527.486 | 486.6462 | 431.9601 | 306.9596 |
| Expenses | 571.8552 | 476.2115 | 439.8007 | 387.3766 | 284.1915 |
| ROE(%) | 19.81 | 11.93 | 10.08 | 9.38 | 4.71 |
Corporate Action
| XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
|---|
Peers
Other companies within the same industry or sector that are comparable to Anuh Pharma Ltd
| Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
|---|---|---|---|---|---|---|
| Albert David Ltd | 808.20 | -1.14 | 11.41 | 87.55 | 1321.50 | 1.42 |
| Lotus Eye Hospital and Institute Ltd | 57.06 | -0.77 | 237.75 | 319.02 | 14.01 | 0.88 |
| Vaishali Pharma Ltd | 12.12 | -5.90 | 606.00 | 164.43 | 2.31 | 0.00 |
| Astec Lifesciences Ltd | 653.90 | -5.55 | 0.00 | 300.80 | -239.30 | 0.00 |
Company Info
1961 - Anuh Pharma Ltd was incorporated. 2006 - In early January, the promoters sold off nearly 14.9% of their stake in the company. -Anuh Pharma has given the Bonus in the Ratio of 1:1 -Company has splits its Face value of Shares from Rs 10 to Rs 5 2010 -Anuh Pharma has given the Bonus in the Ratio of 2:1 2011 -Anuh Pharma has recommended a Dividend of Rs. 5.00 per share of face value of Rs. 5.00. 2012 -Anuh Pharma Ltd has entered into a Memorandum of Understanding with M/s. Invent Pharma Pvt. Ltd., to acquire all fixed assets of their Research & Development Laboratory. -Anuh Pharma has recommended a dividend of Rs. 5.50 per equity share of face value of Rs. 5.00. 2013 -Anuh Pharma has recommended a dividend of Rs. 6.00 per equity share of face value of Rs. 5.00. 2014 -Anuh Pharma Ltd have received approval from COFEPRIS (Health Authority of Mexico) GMP certificate for three of Companys Erythromycin products namely Erythromycin Estolate, Erythromycin Ethyl Succinate & Erythromycin Stearate. -Anuh Pharma has recommended a Final Dividend of Rs. 6.50 (130%) per share. 2015 -The Company has allotted the Bonus Shares to its shareholders in the Ratio of 2:1. 2016 -Anu Pharma Ltd has received EUGMP Certificate granted by ANSM - France. 2020 -The Company has issued Bonus Shares in the Ratio of 1:1.
1961 - Anuh Pharma Ltd was incorporated. 2006 - In early January, the promoters sold off nearly 14.9% of their stake in the company. -Anuh Pharma has given the Bonus in the Ratio of 1:1 -Company has splits its Face value of Shares from Rs 10 to Rs 5 2010 -Anuh Pharma has given the Bonus in the Ratio of 2:1 2011 -Anuh Pharma has recommended a Dividend of Rs. 5.00 per share of face value of Rs. 5.00. 2012 -Anuh Pharma Ltd has entered into a Memorandum of Understanding with M/s. Invent Pharma Pvt. Ltd., to acquire all fixed assets of their Research & Development Laboratory. -Anuh Pharma has recommended a dividend of Rs. 5.50 per equity share of face value of Rs. 5.00. 2013 -Anuh Pharma has recommended a dividend of Rs. 6.00 per equity share of face value of Rs. 5.00. 2014 -Anuh Pharma Ltd have received approval from COFEPRIS (Health Authority of Mexico) GMP certificate for three of Companys Erythromycin products namely Erythromycin Estolate, Erythromycin Ethyl Succinate & Erythromycin Stearate. -Anuh Pharma has recommended a Final Dividend of Rs. 6.50 (130%) per share. 2015 -The Company has allotted the Bonus Shares to its shareholders in the Ratio of 2:1. 2016 -Anu Pharma Ltd has received EUGMP Certificate granted by ANSM - France. 2020 -The Company has issued Bonus Shares in the Ratio of 1:1.
Read More
Parent Organisation
Anuh Pharma Ltd.
Founded
19/02/1960
Managing Director
Mr.Ritesh B Shah
NSE Symbol
ANUHPHREQ
FAQ
The current price of Anuh Pharma Ltd is ₹ 153.52.
The 52-week high for Anuh Pharma Ltd is ₹ 156.95 and the 52-week low is ₹ 153.00.
The market capitalization of Anuh Pharma Ltd is currently ₹ 769.32. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Anuh Pharma Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Anuh Pharma Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Anuh Pharma Ltd shares.
The CEO of Anuh Pharma Ltd is Mr.Ritesh B Shah, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.
